185 related articles for article (PubMed ID: 19650117)
21. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
[TBL] [Abstract][Full Text] [Related]
22. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
23. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
24. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
25. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Nick H; Allegrini PR; Fozard L; Junker U; Rojkjaer L; Salie R; Niederkofler V; O'Reilly T
Exp Biol Med (Maywood); 2009 May; 234(5):492-503. PubMed ID: 19234060
[TBL] [Abstract][Full Text] [Related]
26. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
[TBL] [Abstract][Full Text] [Related]
27. Oral iron chelators.
Cappellini MD; Pattoneri P
Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568
[TBL] [Abstract][Full Text] [Related]
28. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.
Ghoti H; Fibach E; Merkel D; Perez-Avraham G; Grisariu S; Rachmilewitz EA
Haematologica; 2010 Aug; 95(8):1433-4. PubMed ID: 20421274
[No Abstract] [Full Text] [Related]
29. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
[TBL] [Abstract][Full Text] [Related]
30. The administration of deferasirox in an iron-overloaded dialysis patient.
Tsai CW; Yang FJ; Huang CC; Kuo CC; Chen YM
Hemodial Int; 2013 Jan; 17(1):131-3. PubMed ID: 22549006
[No Abstract] [Full Text] [Related]
31. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Koh KN; Park M; Kim BE; Im HJ; Seo JJ
J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
[TBL] [Abstract][Full Text] [Related]
32. Iron chelation therapy as a treatment for Pythium insidiosum in an animal model.
Zanette RA; Alves SH; Pilotto MB; Weiblen C; Fighera RA; Wolkmer P; Flores MM; Santurio JM
J Antimicrob Chemother; 2013 May; 68(5):1144-7. PubMed ID: 23329785
[TBL] [Abstract][Full Text] [Related]
33. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
[TBL] [Abstract][Full Text] [Related]
35. Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
Cancado R; Olivato MC; Bruniera P; Szarf G; de Moraes Bastos R; Rezende Melo M; Chiattone C
Acta Haematol; 2012; 128(2):113-8. PubMed ID: 22760067
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
[TBL] [Abstract][Full Text] [Related]
37. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin.
Sechaud R; Robeva A; Belleli R; Balez S
Int J Clin Pharmacol Ther; 2008 Oct; 46(10):519-26. PubMed ID: 18826866
[TBL] [Abstract][Full Text] [Related]
38. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.
Taher A; Al Jefri A; Elalfy MS; Al Zir K; Daar S; Rofail D; Baladi JF; Habr D; Kriemler-Krahn U; El-Beshlawy A
Acta Haematol; 2010; 123(4):220-5. PubMed ID: 20424435
[TBL] [Abstract][Full Text] [Related]
39. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
40. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
Chauzit E; Bouchet S; Micheau M; Mahon FX; Moore N; Titier K; Molimard M
Ther Drug Monit; 2010 Aug; 32(4):476-81. PubMed ID: 20386360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
